Login to Your Account

Amgen Submits Fast-Track Palifermin BLA In Mucositis

By Kim Coghill

Friday, June 25, 2004
Amgen Inc. is requesting U.S. regulatory approval under fast-track guidelines for palifermin, a first-in-class investigational compound for oral mucositis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription